NYSE:IQVLife Sciences
A Look At IQVIA Holdings (IQV) Valuation After Strong 2025 Results And New Obesity Research Collaboration
IQVIA Holdings (IQV) is back in focus after closing 2025 with revenue and EPS growth near double digits, record R&D Solutions net bookings, and a new obesity research collaboration with Duke Clinical Research Institute.
See our latest analysis for IQVIA Holdings.
Despite the recent obesity research collaboration and solid year-end results, IQVIA Holdings’ share price has come under pressure, with a 30 day share price return of 29.62% and a 1 year total shareholder return of 13.31%. This...